4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Sarcomere based Signals in Muscle Remodelling (SARCOSI)
Date du début: 1 avr. 2012, Date de fin: 31 mars 2016,
The sarcomere is the structural unit of striated muscle tissues where thick and thin filaments cooperate to achieve muscle contraction. Recently it is becoming increasingly clear that sarcomeres have in addition to muscle contraction also important signaling functions: Stretch and strain sensing signalosomes are assembled by the giant muscle proteins titin and nebulin, that in turn are embedded in ...
Voir le projet
14
Participants partenaires
TERMINÉ
The COMET (Core Outcome Measures in Effectiveness Trials) Initiative (COMET)
Date du début: 1 oct. 2012, Date de fin: 31 déc. 2014,
"Clinical trialists often struggle when trying to choose the outcomes to measure which would be of most use to the patients, practitioners and policy makers who will use their research to help them make decisions. These difficulties are passed on to those producing and reading systematic reviews, many of whom have experienced the frustration of finding that the original researchers either did not ...
Voir le projet
11
Participants partenaires
TERMINÉ
Genetic testing in Europe - Network for the further development, harmonization, validation and standardization of services (EUROGENTEST2)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2013,
EuroGentest is an FP6 European network for the harmonization of genetic testing and for the further improvement of quality in genetic services across Europe.This proposal is to support EuroGentest2, a Coordination Action that will cover the different aspects of quality assurance of genetic practice and has all the ingredients to fulfil the needs. EuroGentest2 will be concerned with setting the tar ...
Voir le projet
22
Participants partenaires
TERMINÉ
Bench-to-beside Integrated approach to familial hypertrophic cardiomyopathy: to the HEART of the disease (Big-Heart)
Date du début: 1 janv. 2010, Date de fin: 30 juin 2013,
Hypertrophic cardiomyopathy (HCM), characterised by left ventricular hypertrophy and myocyte disarray, is by far the most common cardiac single gene disorder. With a prevalence of 1:500, HCM is predicted to affect approximately one million people within the EU. HCM represents an important clinical problem, being the principal cause of sudden death in young adults, and a valuable opportunity to use ...
Voir le projet